News

(Editors note: January 22, 2026. Following publication of this joint statement from the National Bleeding Disorders Foundation (NBDF) and the World Federation…

Good news: the House has reintroduced the HELP Copays Act, aimed at ending copay accumulator adjustor programs and copay maximizers. Learn how…

The National Bleeding Disorders Foundation (NBDF) has joined with World Federation of Hemophilia (WFH) with issuing a joint statement on a severe…

NBDF is proud to announce the 2025 recipients of the Judith Graham Pool Postdoctoral Research Fellowship, the NEHA Postdoctoral Research Fellowship, the…

Results from a phase 2 clinical trial of an investigational therapy for the treatment for Glanzmann thrombasthenia were announced by Hemab Therapeutics….

A look inside the legislation to reopen the government after the fall shutdown, a new Medicaid drug pricing model, and changes at…

Star Therapuetics has shared an update on its ongoing clinical trial of VGA039, an investigational therapy for von Willebrand disease. The therapy…

The bill aims to require insurers and pharmacy benefits managers to count all payments, including copay assistance, towards patients’ annual deductibles. Learn…

CSL Behring has published five years of data from their clinical trial of Hemgenix®, a gene therapy product for the treatment of…

This video showcases the Bleeding Disorders Research Collaborative (BDRC), a groundbreaking initiative led by the National Bleeding Disorders Foundation to transform research…

The National Bleeding Disorders Foundation (NBDF) is launching Educate to Elevate, a multi-year initiative to raise public awareness, educate communities, and improve healthcare…

At the 2025 Chapter Leadership Summit (CLS), the National Bleeding Disorders Foundation (NBDF) celebrated the generosity of chapter contributions to research.  For…

The three new recommendations concern off-label use for emicizumab for acquired hemophilia A; the use of anti-tissue factor pathway Inhibitors in hemophilia;…

BioMarin has decided to pursue allowing another company to market and sell ROCTAVIAN, its one-time gene therapy used to treat adults with…

Join us for an educational program about Hemlibra at GLHF’s new office, 12700 W. Bluemound Rd., Suite 130, Elm Grove, on Tuesday,…

The U.S. FDA approved Takeda’s supplemental Biologics License Application (sBLA) for Von Vendi, to expand its indication for routine prophylaxis to reduce…

Nearly 400 people with hemophilia joined gene therapy trials, and shared their data to help future generations. The WFH Gene Therapy Registry…

Mim8 (denecimig) is an injection therapy for preventing bleeds in people with hemophilia A with or without inhibitors. Antibody-based, Mim8 is designed…

Gene therapy has received some doubtful news: not about its effectiveness, but about cost and slow acceptance. Here’s some good news: two…

A new pilot study reveals how social determinants of health disproportionately affect underserved groups — including Black, Indigenous, and Hispanic/Latino individuals —…

Star Therapeutics has raised $125 million to propel the development of VGA039, a subcutaneous monoclonal antibody targeting Protein S. This investigational therapy…

Novo Nordisk has filed for FDA approval of denecimig (Mim8), an investigational subcutaneous therapy designed to treat people with hemophilia A with…

In this webinar, you’ll learn about the gaps that exist in modern research, and how Community Voices in Research uses lived experiences…

NBDF’s Pathway to Cures is investing in cutting edge technology and new approaches to bleeding disorders therapies. Learn more about Be Biopharma,…